Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$1.3 - $3.84 $1,934 - $5,713
1,488 Added 41.1%
5,108 $7,000
Q1 2022

May 13, 2022

BUY
$3.85 - $8.2 $2,375 - $5,059
617 Added 20.55%
3,620 $14,000
Q4 2021

Feb 15, 2022

BUY
$5.71 - $13.15 $17,147 - $39,489
3,003 New
3,003 $24,000

Others Institutions Holding EFTR

About eFFECTOR Therapeutics, Inc.


  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Penserra Capital Management LLC Portfolio

Follow Penserra Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Penserra Capital Management LLC with notifications on news.